[1]毛丽萍,何义民,韩 刚,等.血浆Dickkopf同源物1检测对肝细胞癌的诊断价值[J].现代检验医学杂志,2016,31(05):62-65.[doi:10.3969/j.issn.1671-7414.2016.05.016]
　MAO Li-ping,HE Yi-min,HAN Gang,et al.Diagnosis Value of Detecting Plasma Dickkopf-1 Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(05):62-65.[doi:10.3969/j.issn.1671-7414.2016.05.016]
点击复制

血浆Dickkopf同源物1检测对肝细胞癌的诊断价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第31卷
期数:
2016年05期
页码:
62-65
栏目:
论著
出版日期:
2016-10-21

文章信息/Info

Title:
Diagnosis Value of Detecting Plasma Dickkopf-1 Patients with Hepatocellular Carcinoma
文章编号:
1671-7414(2016)05-062-04
作者:
毛丽萍1; 何义民1; 韩 刚1; 王跃国2
1.南通市第三人民医院检验科,江苏南通 226006;
2.南通大学附属医院,江苏南通 226001
Author(s):
MAO Li-ping1; HE Yi-min1; HAN Gang1; WANG Yue-guo2
1.Department of Clinical Laboratory, the Third People's Hospital of Nantong City,Jiangsu Nantong 226006,China;
2.Department of Clinical Laboratory,Affiliated Hospital of Nantong University,JiangsuNantong 226001,China
关键词:
肝细胞癌;  Dickkopf 同源物1;  甲胎蛋白
分类号:
R735.7; R730.43
DOI:
10.3969/j.issn.1671-7414.2016.05.016
文献标志码:
A
摘要:
目的 探讨检测血浆Dickkopf同源物1(DKK1)对肝细胞癌(HCC)的诊断价值。方法 选取2014年11月～2015年12月南通市第三人民医院已确诊的HCC患者48例,肝硬化(LC)20例,慢性乙型肝炎(CHB)20例,选择排除其他慢性疾病的健康体检者(HC)20例,采用ELISA方法定量检测血浆中DKK1浓度,同时采用美国雅培i2000微粒子化学发光免疫分析仪检测其AFP。同时比较分析其ROC曲线及相关性。结果 HCC组DKK1水平均显著高于LC组、CHB组和HC组(Z=-4.132～-5.828,P均<0.001)。DKK1对HCC诊断价值的ROC曲线下面积为0.889,95%置信区间为0.831～0.947,DKK1诊断HCC最佳cutoff值为565 ng/L,其诊断灵敏度为93.8%,特异度为70%,AFP的ROC曲线下面积为0.759,95%置信区间为0.667～0.850。DKK1的AUC显著>AFP(Z=2.28,P=0.022)。DKK1和AFP两指标间无相关性(r=0.148,P=0.316),其中有21例AFP<20 μg/L而其DKK1>565 ng/L的诊断临界值。结论 检测血浆中DKK1可以作为AFP诊断HCC的有效补充,尤其是DKK1对AFP阴性HCC患者的早期诊断价值值得关注。
Abstract:
Objective To evaluate the diagnosis value of plasma Dickkopf-1(DKK1)in hepatocellular carcinoma(HCC)patients.Methods Selected 48 patients with HCC,20 patients with liver cirrhosis(LC), 20 patients with chronic hepatitis B(CHB),and all of them were clinically diagnosed in the Third People's Hospital of Nantong City,chose 20 cases ofhealth examination as healthy controls(HC),that were ruled out other chronic disease.Enzyme-linked immunosorbent assay(ELISA)and Abbott i2000 microparticle chemiluminescence immunoassay analyzer were used to determine the plasma DKK1and alpha-fetoprotein(AFP)levels.At the same time, analysesed and comparedthe receiver operating characteristic(ROC)curve and correlation of the DKK1 and AFP results.Results The plasma level of DKK1 in patients with HCC was significantly higher than that in patients with chronic hepatitis B,cirrhosis and healthy controls(Z=-4.132～-5.828,P<0.001).The areaunder ROC curve(AUC)of plasma DKK1 in the diagnosis of HCC was 0.889 and 95%confidence interval was 0.831～0.947,when the Cut-off value of DKK1 was 565ng/L,the sensitivity was 93.8% and specificity was 70% in diagnosing HCC.Theareaunder ROC curve of AFP in the diagnosis of HCC was 0.759 and 95% confidenceinterval was 0.667～0.850.The AUC of DKK1 was significantly higher than thatof AFP(Z=2.28,P=0.022).DKK1 and AFP in diagnosing HCC were no significantly correlated(r=0.148,P=0.316).21 patients with AFP under 20 μg/L showed higer DKK1 above 565 ng/L in 48 patients with HCC.ConclusionDetection of DKK1 in plasma can be used as a complement of AFP in thediagnosis of HCC,Especially DKK1 early diagnostic value of AFP negative HCC patients is remarkable.

参考文献/References:

[1] Maluccio M,Covey A.Recent progress in understa-nding,diagnosing,and treating hepatocellular carcinoma[J].CA Cancer J Clin,2012,62(6):394-399.
[2] Vullierme MP,Paradis V,Chirica M,et al.Hepatocellular carcinoma--what's new[J].J Visc Surg,2010; 147(1):e1-12.
[3] 杨 颖,木尼热·马合苏提,包永江,等.GP73和AFP单项与联合诊断原发性肝癌的价值[J].中华检验医学杂志,2012,35(11):1034-1037. Yang Y,Munire·MHST,Bao YJ,et al.Diagnostic value of Golgl-73 and AFP alone or combination in primary hepatocelluar carcinoma[J].Chinese Journal of Laboratory Medicine,2012,35(11):1034-1037.
[4] Sengupta B,Siddiqi SA.Hepatocellular carcinoma:important biomarkers and their significance in molecular diagnostics and therapy[J].Curr Med Chem,2012,19(22):3722-3729.
[5] Malaguarnera G,Giordano M,Paladina I,et al.Serum markers of hepatocellular carcinoma[J].Dig Dis Sci,2010,55(10):2744-2755.
[6] Wang WW,Ang SF,Kumar R,et al.Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma[J].PLoS One,2013,8(7):e68904.
[7] 王芳胜,熊敦勇,寇 辉,等.血清AFP,CEA,CA-199与TAP在肝癌诊断中的应用价值[J].现代检验医学杂志,2015,30(5):148-150. Wang FS,Xiong DY,Kou H,et al.Application value of serum AFP,CEA,CA-199 and TAP in the diagnosis of hepatocellular carcinoma[J].Journal ofModern Laboratory Medicine,2015,30(5):148-150.
[8] Cadigan KM,Nusse R.Wnt signaling:A common theme in animal development[J].Genes Dev,1997,11(24):3286-3305.
[9] Giles RH,van ES JH,Clevers H.Caught up in a wnt storm: Wnt signalingin cancer[J].Biochim Biophys Acta,2003,1653(1):1-24.
[10] Shen Q,Fan J,Yang XR,et al.Serum DKK1 as a protein biomarkerfor the diagnosis of hepatocellular carcinoma:a large-scale,multicentre study[J].Lancet Oncol,2012,13(8):817-826.
[11] Ueland T,Otterdal K,Lekva T,et al.Dickkopf-1 enhances inflammatoryinteraction between platelets and endothelial cells and shows increased expression in atherosclerosis[J].Arterioscler Thromb Vasc Biol,2009,29(8):1228-1234.
[12] Voorzanger Rousselot N,Goehrig D,Facon T,et al.Platelet is a major contributor to circulating levels of Dickkopf-1:clinical implications in patients with multiple myeloma[J].Br J Haematol,2009,145(2):264-266.
[13] 梁卫明,陈义雄,戴 维,等.肝癌患者手术前后、介入治疗前后血清糖蛋白Dickkopf-1水平的变化[J].中华实验外科杂志,2013,30(4):834-835. Liang WM,Chen YX,Dai W,et al.Serum Dickkopf-1 changes before and after operation and interventional therapy in patients with primary liver carcinoma[J].Chinese Journal of Experimental Surgery,2013,30(4):834-835.
[14] Caneparo L,Huang YL,Staudt N,et al.Dickkopf-1 regulates gastrulation movements by coordinated modulation of Wnt /beta catenin and Wnt /PCP activities,through interaction with the Dally-like homolog Knypek[J].Genes Dev,2007,21(4):465-480.

相似文献/References:

[1]邓旭,王晓亮.肝细胞癌患者血清趋化因子CXCR12和SA的表达及临床意义[J].现代检验医学杂志,2015,30(06):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
　DENG Xu,WANG Xiao-liang.Expression and Clinical Significance of Serum CXCR12 and SA in Patients with Hepatocarcinoma[J].Journal of Modern Laboratory Medicine,2015,30(05):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
[2]阮瑞杨,陈修荣,赵世元.抗EZH2自身抗体IgG在肝癌患者血清中的表达及意义[J].现代检验医学杂志,2017,32(02):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
　RUAN Rui-yang,CHEN Xiu-rong,ZHAO Shi-yuan.Expression and Significance of Anti EZH2 Autoantibodies IgG in Hepatocellular Carcinoma Patient's Serum Samples[J].Journal of Modern Laboratory Medicine,2017,32(05):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
[3]隆绍平,邓世群,赵世元.PTPN12蛋白表达下调与原发性肝细胞癌患者复发和预后关系研究[J].现代检验医学杂志,2018,33(01):86.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　LONG Shao-ping,DENG Shi-qun,ZHAO Shi-yuan.Association between Downregulation of PTPN12 Protein and Recurrence and Prognosis in Patients with Primary Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(05):86.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[4]毛丽萍,王跃国,王 健,等.CMIA法测定血清DCP与AFP对肝细胞癌的诊断价值[J].现代检验医学杂志,2018,33(06):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
　MAO Li-ping,WANG Yue-guo,WANG Jian,et al.Diagnostic Value of the Serum DCP and AFP Determined by CMIA in Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(05):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
[5]吴良银a,李文丽b,刘 俊a.肝细胞癌患者生存预后相关长链非编码RNA(LncRNA)的生物信息学分析[J].现代检验医学杂志,2019,34(04):18.[doi:10.3969/j.issn.1671-7414.2019.04.005]
　WU Liang-yina,LI Wen-lib,LIU Juna.Bioinformatics Analysis of Long-Chain Non-Coding RNA Related to Survival and Prognosis in Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2019,34(05):18.[doi:10.3969/j.issn.1671-7414.2019.04.005]
[6]吴良银a,李文丽b,刘　俊b.基于GEO数据的病毒相关性肝癌潜在生物基因标志物的筛选及生物信息学分析[J].现代检验医学杂志,2021,36(06):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
　WU Liang-yin,LI Wen-li,LIU Jun.Screening and Bioinformatics Analysis of Potential Biomarkers for Virus-associated Hepatocellular Carcinoma Based on GEO Data[J].Journal of Modern Laboratory Medicine,2021,36(05):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
[7]陈 偲,李忠辉a,王 颖b.miR-198 通过靶向ZEB2 调控EMT 过程抑制肝癌细胞增殖和迁移的机制研究[J].现代检验医学杂志,2022,37(04):23.[doi:10.3969/j.issn.1671-7414.2022.04.005]
　CHEN Si,LI Zhong-huia,WANG Yingb.Study on the Mechanism of miR-198 Inhibiting the Proliferation and Migration of Hepatoma Cells by Regulating EMT Process by Targeting ZEB2[J].Journal of Modern Laboratory Medicine,2022,37(05):23.[doi:10.3969/j.issn.1671-7414.2022.04.005]
[8]王 路,叶 莎,韩 霞,等.循环外泌体miRNA 检测对肝细胞癌临床诊断效能的Meta 分析[J].现代检验医学杂志,2022,37(04):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
　WANG Lu,YE Sha,HAN Xia,et al.Meta-Analysis of the Diagnostic Value of Circulating Exosomes miRNA Detection for Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2022,37(05):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
[9]时晓晓a,董 翔a,于若卉b,等.miR-203a-3p 靶向GLS1 调控HCC 细胞增殖、迁移、侵袭的机制研究[J].现代检验医学杂志,2022,37(05):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]
　SHI Xiao-xiaoa,DONG Xianga,YU Ruo-huib,et al.Mechanism of miR-203a-3p Targeting GLS1 to Regulate the Proliferation, Migration and Invasion of HCC Cells[J].Journal of Modern Laboratory Medicine,2022,37(05):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]
[10]吴翠婷,周雪辉,张婉馨.基于生物学信息分析筛选晚期肝细胞癌患者接受PD-1 抑制剂治疗后糖酵解相关基因差异表达并构建生存获益模型与验证[J].现代检验医学杂志,2023,38(05):34.[doi:10.3969/j.issn.1671-7414.2023.05.007]
　WU Cuiting,ZHOU Xuehui,ZHANG Wanxin.Differential Expression of Glycolysis-related Genes in Patients with Advanced Hepatocellular Carcinoma Treated with PD-1 Inhibitors Screened Based on Biological Information Analysis, and Survival Benefit Model Constructed and Verified[J].Journal of Modern Laboratory Medicine,2023,38(05):34.[doi:10.3969/j.issn.1671-7414.2023.05.007]

备注/Memo

备注/Memo:
基金项目:2014年度南通市“226工程”培养对象科研项目资助,基金号:CR201401。
作者简介:(1970-),女,主任技师,主要从事分子生物学和免疫学研究。
通讯作者:王跃国(1967-),男,主任技师,主要从事微生物学和免疫学检验研究。
更新日期/Last Update: 2016-10-30